EUCTR2010-020998-16-IT进行中（未招募）不适用
A Phase III randomized study evaluating the efficacy and safety of continued and re-induced bevacizumab in combination with chemotherapy for patients with locally recurrent or metastatic breast cancer after first-line chemotherapy and bevacizumab treatment. - TANIA
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 488
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Signed informed consent prior to initiation of any study-specific procedures or treatment, as confirmation of the patient’s awareness and willingness to comply with the study requirements 2. Female patients =18 years of age 3. Histologically confirmed HER2-negative adenocarcinoma of the breast with documented progression of disease per investigator assessment following or during first-line treatment with bevacizumab in combination with chemotherapy for LR or mBC; patients can have measurable or non-measurable disease. 4. A minimum of 4 cycles of bevacizumab 15 mg/kg or 6 cycles 10 mg/kg received in the first-line setting. Note: patients who have received bevacizumab treatment as part of (neo-) adjuvant therapy are eligible but these bevacizumab cycles do not count towards the minimum required number of cycles. 5. Patients must have received bevacizumab in combination with chemotherapy. Patients may have received: • Bevacizumab monotherapy • Bevacizumab in combination with endocrine treatment • Endocrine treatment • Nothing as part of their maintenance treatment. 6. ECOG performance status (PS) of 0 or 2 7. At least 28 days since prior radiation therapy or surgery and recovery from treatment 8. Estimated life expectancy of =12 weeks
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Disease-specific exclusions 1. Patients who have received anti-angiogenic therapy or anti-vascular endothelial growth factors other than bevacizumab for the first-line treatment of LR/mBC 2. Patients who have exclusively received endocrine treatment in combination with bevacizumab until the first progression 3. Positive or unknown HER2/neu status or for whom determination of HER2 status is not possible. In general, HER2-positive status will be identified by a FISH assay as evaluated at the institution, or, if FISH is unavailable, a 2+ or 3+ immunohistochemistry result. 4. Current, recent (within 4 weeks or 2 half-lives, whichever is greater, before day 1 of cycle 1) or planned participation in an experimental drug study - other than a bevacizumab breast cancer study. 5. Active malignancy, other than superficial basal cell and superficial squamous cell, or carcinoma in situ of the cervix or breast within the last 5 years 6. Any laboratory values at baseline as follows: Hematology: ANC <1.5x10E9/L or 1500/mm3 Platelet count <75x10E9/L Hemoglobin <8 g/dL Coagulation: INR >1.5 except for patients on stable anticoagulant therapy aPTT =1.5 times ULN or greater than the lower limit of the therapeutic range Note: The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits and the patient has been on a stable dose of anticoagulants for at least two weeks at the time of Day 1, Cycle 1. Serum chemistry: Total bilirubin >1.5 times ULN AST or ALT >2 times ULN ALP >2 times ULN 7. Inadequate renal function, defined as: Creatinine clearance <50 mL/min Urine dipstick for proteinuria =2+ unless a 24-hour protein =1 g is demonstrated 8. Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would prevent the patient from meeting the study requirements 9. Serious active infection requiring i.v. antibiotics and/or hospitalization at study entry 10. Patients who are treated with any medicinal product that contraindicates the use of any of the study drugs, may interfere with the planned treatment, affects patient compliance or puts the patient at high risk for treatmentrelated complications. Et al.
研究者
相似试验
进行中（未招募）
不适用
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapyocally recurrent (LR) or metastatic breast cancer (mBC) progressing after first-line chemotherapy and bevacizumab treatment.MedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-020998-16-HUF. Hoffmann-La Roche Ltd494
进行中（未招募）
1 期
A Phase III randomized study evaluating the efficacy and safety of continued and re-induced bevacizumab in combination with chemotherapy for patients with locally recurrent or metastatic breast cancer after first-line chemotherapy and bevacizumab treatment. - TANIAocally recurrent (LR) or metastatic breast cancer (mBC) progressing after first-line chemotherapy and bevacizumab treatment.MedDRA version: 12.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2010-020998-16-SKF. Hoffmann-La Roche Ltd488
进行中（未招募）
不适用
A Phase III randomized study evaluating the efficacy and safety of continued and re-induced bevacizumab in combination with chemotherapy for patients with locally recurrent or metastatic breast cancer after first-line chemotherapy and bevacizumab treatment. - TANIAEUCTR2010-020998-16-GRF. Hoffmann-La Roche Ltd488
进行中（未招募）
不适用
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and ChemotherapyEUCTR2010-020998-16-ATF. Hoffmann-La Roche Ltd494
进行中（未招募）
不适用
ot applicableocally recurrent (LR) or metastatic breast cancer (mBC) progressing after first-line chemotherapy and bevacizumab treatment.MedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-020998-16-DEF. Hoffmann-La Roche Ltd488